

1647

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number 09/580,018

Filing Date May 26, 2000

First Named Inventor Schenk, Dale B.

Group Art Unit 1647

Examiner Name Nichols, Christopher J.

Total Number of Pages in This Submission

15

Attorney Docket Number

15270J-004760US

**ENCLOSURES (check all that apply)**☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Response☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Supplemental Information  
Disclosure Statement  
(14 pp) 17 volumes of references (nos.  
1-339)☐ Certified Copy of Priority  
Document(s)☐ Response to Missing Parts/  
Incomplete Application☐ Response to Missing  
Parts under 37 CFR  
1.52 or 1.53☐ Assignment Papers  
(for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition Routing Slip (PTO/SB/69)  
and Accompanying Petition☐ Petition to Convert to a  
Provisional Application☐ Power of Attorney, Revocation  
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s)☐ After Allowance Communication to  
Group☐ Appeal Communication to Board of  
Appeals and Interferences☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s)  
(please identify below):

1. Return Postcard (1pg)

Remarks

The Commissioner is authorized to charge any additional fees to  
Deposit Account 20-1430.

\* Note: References not included in total number of pages.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm  
and  
Individual name

Townsend and Townsend and Crew LLP

Rosemarie L. Celli

Reg. No. 42,397

Signature

Date

August 22, 2003

**CERTIFICATE OF MAILING**I hereby certify that this correspondence is being delivered, VIA HAND DELIVERY to: US Patent and Trademark Office, 2011  
South Clark Place, Customer Window, Crystal Plaza Two, Lobby, Room 1B03, Arlington, Virginia 22202 on this date:

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60024668 v1

I hereby certify that this correspondence is being delivered by  
Hand Delivery to:

US Patent and Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202



PATENT  
Attorney Docket No.: 15270J-004760US  
Client Reference No.: 209-US-CIP8B

On 9/4/03

By: [Signature]  
PRIOR ART SEARCHES

Application No.: 09/580,018  
Filed: May 26, 2000  
Examiner: Christopher J. Nichols

Confirmation No.: 9973

TC/AU: 1647  
Customer No.: 20350

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants filed Information Disclosure Statements, along with their respective PTO/SB/08A & 08B forms, on November 3, 2000, January 8, 2001, January 8, 2002, and February 18, 2003 for the above-captioned application. In accordance with 37 C.F.R. § 1.98(d), Applicants relied on references previously submitted for U.S. Application No. 09/322,289 or U.S. Application No. 09/201,289. The above-captioned application no longer claims priority under 35 U.S.C. § 120 to U.S. Application Nos. 09/322,289 and No. 09/201,289. Consequently, Applicants can no longer rely on § 1.98(d) and, therefore, submit copies of the references cited by the above-mentioned Information Disclosure Statements herewith.

The following table lists the previously cited references.

1	6,057,367		05-02-2000	Stamler et al.
2	5,958,883		09-28-1999	Snow
3	5,955,317		09-21-1999	Suzuki et al.
4	5,955,079		09-21-1999	Mond et al.



5		5,877,399		03-02-1999	Hsiao et al.
6		5,869,093		02-09-1999	Weiner et al.
7		5,869,054		02-09-1999	Weiner et al.
8		5,854,204		12-29-1998	Findeis et al.
9		5,851,996		12-22-1998	Kline
10		5,849,298		12-15-1998	Weiner et al.
11		5,837,473		11-17-1998	Maggio et al.
12		5,786,180		07-28-1998	Konig et al.
13		5,753,624		05-19-1998	McMichael et al.
14		5,750,349		05-12-1998	Suzuki et al.
15		5,733,547		03-31-1998	Weiner et al.
16		5,688,651		11-18-1997	Solomon
17		5,679,348		10-21-1997	Nesburn et al.
18		5,645,820		07-08-1997	Hafler et al.
19		5,641,474		06-24-1997	Hafler et al.
20		5,641,473		06-24-1997	Hafler et al.
21		5,612,486		03-18-1997	McConlogue et al.
22		5,605,811		02-25-1997	Seubert et al.
23		5,585,100		12-17-1996	Mond et al.
24		5,571,500		11-05-1996	Hafler et al.
25		5,571,499		11-05-1996	Hafler et al.
26		5,434,170		07-18-1995	Andrulis, Jr.
27		5,387,742		02-07-1995	Cordell
28		5,231,000		07-27-1993	Majocha et al.
29		5,220,013		06-15-1993	Ponte et al.
30		5,208,036		05-04-1993	Eppstein et al.
31		5,192,753		03-09-1993	McGeer et al.
32		5,187,153		02-16-1993	Cordell et al.
33		5,057,540		10-15-1991	Kensil et al.
34		4,666,829		05-19-1987	Glennner et al.
35	EP	911 036	A2	04-28-1999	
36	EP	868 918	A2	10-07-1998	
37	EP	863 211	A1	09-09-1998	
38	EP	845 270	A1	06-03-1998	
39	EP	782 859	A1	07-09-1997	
40	EP	683 234	A1	11-22-1995	
41	EP	666 080	A1	08-09-1995	
42	EP	652 962	B1	12-16-1998	
43	EP	639 081	B1	11-03-1999	
44	EP	613 007	A2	08-31-1994	
45	EP	594 607	B1	08-27-1997	
46	EP	561 087	B1	08-04-1999	
47	EP	526 511	B1	05-28-1997	
48	EP	506 785	B1	03-15-2000	
49	EP	451 700	A1	10-16-1991	
50	EP	440 619	B1	01-24-1996	
51	EP	359 783	B1	11-29-1995	
52	EP	276 723	B1	12-08-1993	
53	WO	99/60024	A1	11-25-1999	
54	WO	99/60021	A2	11-15-1999	
55	WO	99/58564	A1	11-18-1999	
56	WO	99/06066	A2	02-11-1999	
57	WO	99/27949	A1	06-10-1999	

58	WO	99/27944	A1	06-10-1999	
59	WO	99/27911	A1	06-10-1999	
60	WO	98/44955	A1	10-15-1998	
61	WO	98/07850	A2	02-26-1998	
62	WO	97/17613	A1	05-15-1997	
63	WO	96/39176	A1	12-12-1996	
64	WO	96/25435	A1	08-22-1996	
65	WO	96/18900	A1	06-20-1996	
66	WO	95/31996	A1	11-30-1995	
67	WO	95/11994	A1	05-04-1995	
68	WO	95/11311	A1	04-27-1995	
69	WO	95/05853	A1	03-02-1995	
70	WO	95/04151	A2	02-09-1995	
71	WO	94/03615	A1	02-17-1994	
72	WO	94/01772	A1	01-20-1994	
73	WO	93/21950	A1	11-11-1993	
74	WO	93/16724	A1	09-02-1993	
75	WO	93/15760	A1	08-19-1993	
76	WO	93/14200	A1	07-22-1993	
77	WO	93/02189	A1	02-04-1993	
78	WO	92/13069	A1	08-06-1992	
79	WO	92/06708	A1	04-30-1992	
80	WO	92/06187	A1	04-16-1992	
81	WO	91/19810	A1	12-26-1991	
82	WO	91/16819	A1	11-14-1991	
83	WO	91/12816	A1	09-05-1991	
84	WO	91/08760	A1	06-27-1991	
85	WO	90/12871	A1	11-01-1990	
86	WO	90/12870	A1	11-01-1990	
87	WO	89/01343	A1	02-23-1989	
88	WO	89/06242	A1	07-13-1989	
89	WO	89/06689	A1	07-27-1989	
90	WO	89/03687	A1	05-05-1989	
91	WO	88/10120	A1	12-29-1988	
92	GB	2 220 211	A	01-04-1990	
93	GB	2 335 192	A	09-15-1999	
94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <u>Neurology</u> , 45:1441-1445 (1995).				
95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95).				
96	BAUER et al., "Interleukin-6 and $\alpha$ -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).				
97	BLASS, "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999).				
98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).				
99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).				
100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genetic Develop.</u> , 3: 102-109 (1993).				

101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).
102	CHAO et al., "Transforming Growth Factor- $\beta$ Protects human Neurons Against $\beta$ -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513-7 (1993).
103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995).
104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).
105	FELSENSTEIN et al., "Processing of the $\beta$ -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).
108	FLANDERS et al., "Altered expression of transforming growth factor- $\beta$ in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998).
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).
114	GLENNER et al., "Alzheimer's Disease and Down's Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS USA</u> , 93:427-432 (1996).
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).
118	HAGA et al., "Synthetic Alzheimer amyloid $\beta$ /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).
119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).
121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).
122	HSIAO et al., "Correlative Memory Deficits, A $\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).

123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).
128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).
130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).
131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).
132	LEMERE et al., "Mucosal Administration of A $\beta$ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).
135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).
136	MEDA et al., "Activation of microglial cells by $\beta$ -amyloid protein and interferon- $\gamma$ ," <u>Nature</u> , 374:647-650 (1995).
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
140	PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).
141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).
143	QUON et al., "Formation of $\beta$ -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).
144	RASO, V.A., Grant application # 1 R43 AG1 5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).
145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).

146	ROGERS et al., "Complement activation by $\beta$ -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).
148	SCHENK et al., "Immunization with amyloid- $\beta$ attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).
149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).
151	SELKOE, "Physiological production of the $\beta$ -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's $\beta$ -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).
159	SOLOMON et al., "Disaggregation of Alzheimer $\beta$ -amyloid by site-directed mAb," <u>PNAS USA</u> , 94:4109-4112 (1997).
160	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer $\beta$ -amyloid peptide," <u>PNAS USA</u> , 93:452-455 (1996).
161	SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).
162	SOLOMON, B., "New Approach Towards Fast Induction of Anti $\beta$ -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown).
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum Malaria</i> ," <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997).
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).
166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).
167	VAN GOOL et al., "Concentrations of amyloid- $\beta$ protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).

168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).			
169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).			
170	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-872 (2000).			
171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).			
172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).			
173	WOOD et al., "Amyloid precursor protein processing and A $\beta$ 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS USA</u> , 94: 1550-1555 (1997).			
174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).			
175	5,441,870		08-15-1995	Seubert, et al.
176	BARD et al., "Peripherally administered antibodies against amyloid $\beta$ -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).			
177	HELMUTH, "Further Progress on a $\beta$ -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).			
178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- $\beta$ Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).			
179	SOUTHWICK et al., "Assessment of Amyloid $\beta$ protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).			
180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).			
181	5,270,165		12-14-1993	Van Nostrand et al.
182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's $\beta$ -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).			
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).			
184	LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).			
185	SOLOMON and et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).			
186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).			
187	EP	783 104	A1	07-09-1997
188	WO	00/43049	A1	07-27-2000
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Posts ischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).			
190	GRAVINA et al., "Amyloid $\beta$ Protein (A $\beta$ ) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).			
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of $\beta$ -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).			



192	IWATSUBO et al., "Visualization of A $\beta$ 42(43) and A $\beta$ 40 in Senile Plaques with End-Specific A $\beta$ Monoclonals: Evidence That an Initially Deposited Species Is A $\beta$ 42(43)," <u>Neuron</u> , 13:45-53 (1994).			
193	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of $\beta$ / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).			
194	SAIDO et al., "Spatial Resolution of the Primary $\beta$ -Amyloidogenic Process Induced in Posts ischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).			
195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the $\beta$ A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).			
196	6,150,091		11-21-2000	Pandolfo et al.
197	5,744,368		04-28-1998	Goldgaber et al.
198	5,004,697		04-20-1991	Pardridge
199	WO 00/77178	A1	12-21-2000	
200	WO 95/12815	A1	05-11-1995	
201	WO 94/28412	A1	12-08-1994	
202	WO 97/21728	A1	06-19-1997	
203	WO 99/00150	A2	01-07-1999	
204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> , 29:345-354 (1999).			
205	WO 93/04194	A1	03-04-1993	
206	MORI et al., "Mass Spectrometry of Purified Amyloid $\beta$ Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).			
207	5,780,587		07-14-1998	Potter
208	WO 96/28471	A1	09-19-1996	
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).			
210	FRIEDLAND et al., "Development of an anti-A $\beta$ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).			
211	5,736,142		04-07-1998	Sette et al.
212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> , 18:764 (1992).			
213	CHEN et al., "An Antibody to $\beta$ Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> , 125:223-226 (1991).			
214	DEMATTOS et al., "Peripheral Anti A $\beta$ Antibody Alters CNS And Plasma A $\beta$ Clearance and Decreases Brain A $\beta$ Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA</u> , 10.1073/pnas.151261398 (2001).			
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A $\beta$ <sub>1-42</sub> ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).			
216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> , 138:373-384 (1991).			
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).			
218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for $\beta$ /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> 33:2184-2189 (1992).			
219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>PNAS USA</u> , 82:8729-8732 (1985).			

220	Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. – comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)			
221	5,989,566		11-23-1999	Cobb et al.
222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)			
223	WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)			
224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : <a href="http://www.fda.gov/cber/vaccine/thimerosal.htm">http://www.fda.gov/cber/vaccine/thimerosal.htm</a> , last updated May 16, 2002.			
225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/18/2002).			
226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)			
227	WO	95/11008	A2	04-27-1995
228	BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," <i>J. Mol.Biol.</i> , 225(4): 1075-1093 (1992).			
229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", <i>Immunology</i> , Vol. 78: 643-649 (1993).			
230	6,262,335	B1	07-17-2001	Hsiao et al.
231	6,114,133		09-05-2000	Seubert et al.
232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <i>Laboratory Animal Science</i> , 46(1):8-14 (1996).			
233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <i>Neurology</i> , 39:1159-65 (1989).			
234	6,284,221	B1	09-04-2001	Schenk, et al.
235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-486 (1965).			
236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid $\beta$ A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991).			
237	GORTNER, <i>Outlines of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).			
238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <i>Virology</i> , 243:158-166 (1998).			
239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.			
240	WO	00/43039	A1	07-27-2000
241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-5 (1992).			
242	60/168,594		11-29-1999	Chalifour et al.
243	WO	01/39796	A2	06-07-2001
244	FRENKEL, et al., "Modulation of Alzheimer's $\beta$ -amyloid neurotoxicity by site-directed single chain antibody," <i>J. of Neuroimmunology</i> , 106:23-31 (2000).			
245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of $\beta$ -amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuroimmunology</i> , 95:136-142 (1999).			

246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).
247	FRENKEL et al., "Immunization against Alzheimer's $\beta$ -amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000).
248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's $\beta$ -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998).
249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).
250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995).
251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990).
252	GEDDES, "N-terminus truncated $\beta$ -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999).
253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998).
254	GRUBECK-LOEBENSTEIN, et al., "Immunization with $\beta$ -amyloid: could T-cell activation have a harmful effect?," <u>TINS</u> , 23:114 (2000).
255	HARIGAYA, et al., "Modified amyloid $\beta$ protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995).
256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- $\beta$ protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987).
257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).
258	KIDA, et al., "Early amyloid- $\beta$ deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995).
259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997).
260	LEMERE, et al., "Nasal A $\beta$ treatment induces anti-A $\beta$ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000).
261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994).
262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 196:105-108 (1995).
263	MANN, et al., "Amyloid $\beta$ protein (A $\beta$ ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A $\beta$ <sub>42(43)</sub> ," <u>Annals of Neurology</u> , 40:149-156 (1996).
264	MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992).
265	MENA, et al., "Monitoring pathological assembly of tau and $\beta$ -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995).

266	CHAPMAN, "Model behavior," <u>Nature</u> , 408:915-916 (2000).			
267	6,294,171 B2		09-25-2001	McMichael
268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid $\beta$ protein ( $A\beta$ ) subtypes ( $A\beta$ 40 and $A\beta$ 42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <u>Neuroscience Letters</u> , 201:151-154 (1995).			
269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996).			
270	SCHENK, et al., " $\beta$ -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000).			
271	ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1999).			
272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid $\beta$ -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996).			
273	THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000).			
274	WEINER et al., "Nasal administration of amyloid- $\beta$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000).			
275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997).			
276	TJERNBERG et al., "Arrest of $\beta$ -amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996).			
277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).			
278	SAITOH, N. et al., "Immunological analysis of Alzheimer's disease using anti- $\beta$ -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).			
279	SAITO et al., "Vector-mediated delivery of $^{125}$ I-labeled $\beta$ -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the $A\beta^{1-40}$ vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995).**			
280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987).			
281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998).			
282	60/169,687		12-08-1999	Chain
283	09/441,140		11-16-1999	Solomon et al.
284	5,231,170		07-27-1993	Averback
285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharm.</u> , 15:414A-414B (1992).			
286	CORDELL, B., " $\beta$ -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).			
287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).			
288	DUMERY et al., " $\beta$ -Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).			
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001).			

290	YOUNKIN, "Amyloid $\beta$ vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001).			
291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000).			
292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid $\beta$ protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998).			
293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998).			
294	WO	01/62801	A2	08-30-2001
295		60/184,601		02-24-2000
296		60/254,465		12-08-2000
297		60/254,498		12-08-2000
298	WO	01/42306	A2	06-14-2001
299		60/186,295		03-01-2000
300		2001/0018053 A1		08-30-2001
301	WO	01/62284	A2	03-01-2000
302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid $\beta$ -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999).			
303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998).			
304	RASO, V.A., Grant application # 1 R43 AG1 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).			
305		09/724,842		11-28-2000
306		6,417,178	B1	07-09-2002
307	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-9 (2000).			
308	JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-82 (2000).			
309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <u>Physiol Rev.</u> 77(4):1081-132 (1997).			
310	MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000).			
311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> . 408(6815):982-5 (2000).			
312	SCHENK, et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001).			
313	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998).			
314	SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000).			
315	SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci.</u> , 920:206-8 (2000).			
316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. <u>Nat Med.</u> 4(7):822-6 (1998).			

317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <i>DNA Cell Biol.</i> (11):713-21 (2001).				
318	DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <i>Neurology</i> , 57(5):801-5 (2001).				
319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <i>Nat Rev Neurosci.</i> 2(8):595-8 (2001).				
320	5,593,846			01-14-1997	Schenk et al.
321	5,837,672			11-17-1998	Schenk et al.
322	WO	00/72880	A2, A3	12-07-2000	
323	WO	00/72876	A2, A3	12-07-2000	
324	WO	00/72870	A1	12-07-2000	
325		2001/0102261	A1	08-01-2002	Raso
326		2002/0136718	A1	09-26-2002	Raso
327	CAMERON, "Recent Advances in Transgenic Technology," <i>Molecular Biotechnology</i> , 7:253-265 (1997).				
328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" <i>Alzheimer's and Parkinson's Diseases</i> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).				
329	NIEMANN, "Transgenic farm animals get off the ground;" <i>Transgenic Research</i> 7:73-75 (1998).				
330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <i>Arterioscler Thromb Vasc Biol.</i> , 20:1425-1429 (2000).				
331	WO	99/06545	A2	11-02-1999	
332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," <i>Progress in Brain Research</i> , Van Leeuwen et al. Eds, 117:327-337 (1998).				
333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both $\alpha$ -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <i>PNAS</i> , 97(2):571-576 (2000)				
334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991).				
335	MASLIAH et al., " $\beta$ -Amyloid peptides enhance $\alpha$ -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <i>PNAS</i> , 98(21):12245-12250 (2001).				
336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <i>PNAS</i> , 99(8):5591-5595 (2002).				
337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech.</i> , 18(1):34-39 (2000).				
338	STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <i>The Journal of Neuroscience</i> , 22(17):7380-7388 (September 1, 2002).				
339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <i>PNAS</i> , 92:4299-4303 (1995).				


Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the

Schenk et al.  
Application No.: 09/580,018

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Rosemarie L. Celli". The signature is fluid and cursive, with the first name being the most prominent.

Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:rlc  
60023695 v1